{
    "clinical_study": {
        "@rank": "131382", 
        "brief_summary": {
            "textblock": "The main purpose of this study is to determine the electrophysiological effects of\n      cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer\n      disease.  The attempt will be to locate electrophysiological markers and predictors of\n      cognitive and clinical treatment response."
        }, 
        "brief_title": "Electrophysiologic Measures of Treatment Response in Alzheimer Disease", 
        "completion_date": "September 2001", 
        "condition": "Alzheimer Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state\n        exam scores between 15-27), and normal controls (age generally between 60-85).  Subjects\n        must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or\n        willing to try a transdermal nicotine patch for two 8 hour periods."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "55 Years"
        }, 
        "firstreceived_date": "July 3, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00018278", 
            "org_study_id": "AGCG-004-98S"
        }, 
        "intervention": [
            {
                "intervention_name": "Aricept", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Exelon", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nicoderm Patch", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rivastigmine", 
                "Donepezil"
            ]
        }, 
        "lastchanged_date": "January 20, 2009", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92161"
                }, 
                "name": "Department of Veterans Affairs"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease", 
        "overall_official": [
            {
                "last_name": "Vincente Iragui, M.D., Ph.D"
            }, 
            {
                "last_name": "Shuanna Morris, Ph.D."
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00018278"
        }, 
        "source": "Department of Veterans Affairs", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Department of Veterans Affairs", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "October 1998", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2004"
    }, 
    "geocoordinates": {
        "Department of Veterans Affairs": "32.715 -117.157"
    }
}